PHARMACEUTICAL
Peptide Quality Infrastructure for Pharmaceutical Development
Reference materials, impurity strategy, analytical methods and stability support for pharmaceutical peptide development programs — from preclinical through commercial.
FOCUS AREAS
Quality Infrastructure
Quality Control
Reference materials and analytical methods supporting batch release and QC testing.
Impurity Strategy
Impurity identification, classification and reference material development aligned with regulatory expectations.
Reference Materials
Parent peptide and impurity reference materials with full characterisation documentation.
Analytical Methods
Method development, forced degradation and method validation for regulatory submissions.
Stability
Stability study design, analytical testing and stability data reporting.